

CURRICULUM VITAE

Brian Branchford MD

**Associate Professor
Department of Pediatrics
Division of Hematology and Oncology - Pediatrics
Associate Investigator
Versiti Blood Research Institute
Associate Medical Director
Versiti Medical Science Institute**

OFFICE ADDRESS:

Children's Wisconsin - Milwaukee Hospital
8915 W Connell Court
Milwaukee, WI 53226
Email: bbranchford@mcw.edu

EDUCATION:

1997 - 2001 B.A., Biology, Lawrence University, Appleton
2001 - 2005 M.D., University of Wisconsin School of Medicine and Public Health, Madison, WI

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

2005 - 2008 Pediatric Residency, Children's Hospital of Wisconsin, Milwaukee WI
2008 - 2009 Chief Pediatric Resident, Children's Hospital of Wisconsin, Milwaukee, WI
2009 - 2012 Hematology/Oncology/BMT, Children's Hospital Colorado, Aurora, CO
2012 - 2013 Instructor/Fellow Pediatric Hematology, Children's Hospital Colorado, Aurora, CO

FACULTY APPOINTMENTS:

2013 - 2015 Clinical Instructor, Department of Pediatrics, Division of Hematology/Oncology, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado
2015 - 2020 Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado
2020 - Present Associate Medical Director, Versiti Medical Science Institute
Associate Investigator, Versiti Blood Research Institute
Assistant Professor, Department of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Children's Wisconsin

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

2008 - 2009 Chief Pediatric Resident, Children's Hospital of Wisconsin, Milwaukee WI
2019 - 2020 Director, Thrombosis Program, University of Colorado Hemophilia and Thrombosis Center, Aurora, CO

HOSPITAL STAFF PRIVILEGES:

1312 - Present E 16th Ave
2013 - 2020 Children's Hospital Colorado
2020 - Present Children's Hospital of Wisconsin
9000 - Present W. Wisconsin Ave.
Milwaukee, WI 53226
Aurora, CO 80045

SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
Pediatrics (ABP ID #674322)	2008	2018
Pediatric Hematology - Oncology	2015	None

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Licensure Wisconsin	49760-20	09/19/6	10/31/21

AWARDS AND HONORS:

- 2010 - 2011 American Society of Hematology, Selected for year-long Translational Research Training in Hematology (TRTH) Course
- 2011 - Present International Society of Thrombosis & Hemostasis Annual Meeting, Young Investigator Award
- 2011 - Present Children's Hospital Colorado Springs Poster Session, Best Poster Award
- 2011 - 2019 National Institutes of Health: Loan Repayment Program
- 2011 - Present American Society of Hematology Annual Meeting, Abstract Achievement Award
- 2011 - Present Hemophilia/ Thrombosis Research Society Annual Meeting, Young Investigator Award
- 2011 - Present Gordon Research Seminar (Hemostasis), Best Oral Presentation
- 2012 - Present American Society of Hematology Annual Meeting, Abstract Achievement Award
- 2013 - Present Hemophilia/Thrombosis Research Society Annual Meeting, Junior Investigator Award
- 2013 - Present Hemophilia/Thrombosis Research Society Annual Meeting, Blue Ribbon Poster of Distinction
- 2013 - Present Children's Hospital Colorado, Pillar Award for Outstanding Performance
- 2015 - Present American Society of Hematology Annual Meeting, Abstract Achievement Award
- 2019 - Present Publons, Global Peer Review Award: Top 1% in Field
- 2022 - Present Jacqueline and Arlyn Frederick Award for Clinical Research

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

- 2011 - Present Member (International Society of Thrombosis and Haemostasis (ISTH))
- 2012 - Present Member (American Society of Hemostasis (ASH))
- 2012 - Present Member (Hemostasis and Thrombosis Research Society (HTRS))

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Journal Review

- 2012 - Present Manuscript Peer-Review Referee - Ad Hoc Reviewer. 131 verified reviews (Review statistics at <https://publons.com/researcher/1191335/brian-branchford>)
- 2014 - Present Review Editor - Frontiers in Hematology, Pediatric Immunology
- 2016 - 2018 Guest Associate Editor - Frontiers in Hematology, Pediatric Immunology

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

- 2012 - 2020 Physician Co-Leader, CCBD Process Improvement Group, Hospital- Associated VTE Prevention Division (Pediatric Hematology/Oncology - Center for Cancer and Blood Disorders [CCBD]), Children's Hospital Colorado, Aurora CO
- 2012 - 2020 Co-Leader, Hospital-wide Multidisciplinary Group, Hospital-Associated VTE Prevention Hospital (Children's Hospital Colorado, Aurora CO)
- 2019 - 2020 Member, Clinical Pathways and Measures Committee, Venous Thrombosis Diagnosis and Management, Venous Thromboembolism Prophylaxis, Anticoagulation Dosing and Monitoring
- 2019 - 2020 Hematology Representative, Inpatient Handoff Document Development Team, Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora CO
- 2020 Reviewer, Medical Student Research Day Poster Session, Medical College of Wisconsin, Wauwatosa WI
- 2021 Pediatric Hematology/Oncology Fellowship Interviewer, Medical College of Wisconsin, Wauwatosa WI
- 2021 Faculty Interviewer, Versiti Blood Research Institute and Medical College of Wisconsin, Wauwatosa WI
- 2021 Judge, SAMS/MSSRP Virtual Poster Program, Medical College of Wisconsin, Wauwatosa WI
- 2021 Co-Host PI, BRI Seminar Series, Versiti Blood Research Institute, Wauwatosa WI

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

- 2013 - 2020 National Physician Co-Leader, Children's Hospital Solution for Patient Safety (CHSPS) Committee for Prevention of Hospital-Acquired Conditions, Hospital-Acquired VTE Section
- 2014 - Present Reviewer, Hemostasis and Thrombosis Research Society Mentored Research Awards
- 2014 - Present Co-Founder and Co-Principal Investigator, Children's Hospital-Acquired Thrombosis (CHAT) clinical research consortium
- 2015 Reviewer, Hemostasis and Thrombosis Research Society/American Thrombosis and Hemostasis Network Dataset Research Enrichment and ATHN Membership (DREAM) Awards
- 2016 Reviewer, National Hemophilia Foundation Judith Graham Pool Award
- 2017 - 2019 Member, Data Safety Monitoring Board, Prevention of Central Venous Catheter-Associated in Critically Ill, Children: A Multicenter, Phase 2a Trial: Catheter-Related Early Thromboprophylaxis with Enoxaparin (CRETE) Trial.
- 2017 - Present Member, Venous thromboEmbolism Network United States (VENUS): Pediatric Thrombosis Committee
- 2017 - Present Director, HTRS Board of Directors
- 2018 - Present Member, Clinical Genome Resource (ClinGen) Working Group for Platelet Disorders Working Group for Thrombotic Disorders
- 2019 Reviewer, Hemostasis and Thrombosis Research Society Mid-Career Research Award
- 2019 Reviewer, National Hemophilia Foundation Investigator-Initiated Award
- 2019 Reviewer, University of Colorado Clinical and Translational Sciences Institute: PreK Mock Review Program for K23 Awards
- 2019 Reviewer, University of Colorado Clinical and Translational Sciences Institute: Child and Maternal Health Pilot Grant Program
- 2019 - 2020 Reviewer, American Heart Association Innovative Project Award
- 2020 Reviewer, University of Colorado Clinical and Translational Sciences Institute: Mock National Research Service Award Study Section - F32 Award
- 2020 - Present Member, Hemostasis and Thrombosis Research Society Officer Nominating Committee
- 2020 - Present Member, Preterm Infants Committee, Recipient Epidemiology and Donor Evaluation Study IV-Pediatric (REDS-IV-P) of NIH National Heart Lung Blood Institute, Wisconsin Hub

INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

- 2014 - Present Member, ISTH Working Group for Pediatric Hospital-Acquired Venous Thromboembolism Prevention/Risk Scores
- 2014 - Present Member, Scientific and Standardization Committee, ISTH Pediatric/Neonatal Hemostasis and Thrombosis
- 2017 - Present Executive Committee Member (U.S. Representative), International Pediatric Thrombosis Network
- 2020 - Present Member, ISTH SSC Working Group for Pediatric Thromboprophylaxis
- 2020 - Present Member, Executive Steering Committee: Pediatric Duration of Therapy in Thrombosis 2: Direct Oral Anticoagulants (Kids-DOTT2: DOAC). Principal Investigator: Neil Goldenberg, MD, PhD. Johns Hopkins All Children's Hospital

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:**Active****Peer Review**

Title:	The Role of Inflammation in Platelet Signaling and Thrombosis
Source:	National Institutes of Health, National Heart, Lung, and Blood Institute
Role & Effort:	PI (75% effort)
Dates:	01/2019 - 06/2025
Direct Funds:	\$894,911

Non-Peer Review

Title:	GAS6/Protein S-TAM Signaling & Thrombosis Risk in Pediatric COVID-19
--------	--

Source: MIS-C
Versiti Comprehensive Center for Blood Disorders
Role & Effort: PI
Dates: 10/2021 - 09/2022
Direct Funds: \$50,000

Title: The Role of Protein S in Inflammation-Associated Platelet Signaling
Source: Medical College of Wisconsin/Midwest Athletes Against Childhood Cancer
Role & Effort: PI
Dates: 07/2022 - 06/2023
Direct Funds: \$86,040

Title: The Role of Inflammation in Platelet Activation Signaling and Thrombosis in Children
Source: Versiti Blood Research Foundation
Role & Effort: PI
Dates: 07/2022 - 06/2023
Direct Funds: \$100,000

Prior

Peer Review

Title: Role of the GAS6/TAM Pathway in Platelet Activation Responses
Source: National Hemophilia Foundation and Baxter (now Takeda)
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2010 - 06/2012
Direct Funds: \$200,000

Title: Effect of TAM Pathway Inhibitors on Platelet Activation and Thrombus Formation
Source: National Institutes of Health and University of Colorado School of Medicine
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2013 - 06/2015
Direct Funds: \$200,000

Title: Evaluation of GAS6/TAM Inhibitors as Novel Antiplatelet Agents
Source: CSL Behring
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2013 - 06/2016
Direct Funds: \$20,000

Title: Evaluation of GAS6/TAM Inhibitors as Novel Antiplatelet Agents
Source: American Society of Hematology
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2013 - 06/2015
Direct Funds: \$100,000

Title: Development of GAS6/TAM Inhibitors
as Novel Antiplatelet Agents
Source: Hemostasis and Thrombosis Research
Society
Role & Effort: Principal Investigator (75% effort)
Dates: 01/2014 - 12/2015
Direct Funds: \$150,000

Title: Investigation of Risk Factors for
Pediatric Hospital-Acquired Venous
Thromboembolism
Source: Children's Hospital Colorado
Role & Effort: Principal Investigator (25% effort)
Dates: 07/2014 - 06/20
Direct Funds: \$25,000

Title: Gas6-MERTK Signaling in
Thromboinflammation
Source: Maternal Child Health Bureau/Health
Resources and Services Administration
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2015 - 06/2017
Direct Funds: \$300,000

Title: Crosstalk between Inflammation and
Platelet Activation Signals in Pediatric
Thrombosis
Source: Maternal Child Health Bureau/Health
Resources and Services Administration
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2017 - 06/2020
Direct Funds: \$450,000

Title: The Role of Inflammation in Platelet
Activation and Thrombus Formation
Source: Tanabe-Bobrow Family, Children's
Hospital Colorado Research Foundation
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2019 - 06/2020
Direct Funds: \$50,000

Non-Peer Review

Title: Investigation of Risk Factors for
Pediatric Hospital-Acquired Venous
Thromboembolism
Source: Children's Hospital Colorado
Role & Effort: Principal Investigator (25% effort)
Dates: 07/2014 - 06/20
Direct Funds: \$25,000

Title: The Role of Inflammation in Platelet
Activation and Thrombus Formation
Source: Tanabe-Bobrow Family, Children's
Hospital Colorado Research Foundation
Role & Effort: Principal Investigator (75% effort)
Dates: 07/2019 - 06/2020

Direct Funds:

\$50,000

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

Presenter, "Which Risk Groups of Children Should Receive Prophylaxis?", ISTH Congress, Berlin, Germany, 2017

National

Presenter, "Think Tank on Epidemiology and Translational Studies in Transfusion Medicine, Hemostasis and Thrombosis in Neonatal and Pediatric Populations", NIH-NHLBI, 2012

Presenter, "Rethinking New Technologies to Facilitate Pediatric and Neonatal Clinical Trials in Hemostasis, Thrombosis, and Transfusion Medicine", NIH-NHLBI Working Group, 2012

Presenter, "Novel Gas6/TAM Inhibitors decrease platelet activation and thrombus formation", Pediatric Hematology/Oncology Section Meeting, Cincinnati Children's Hospital Medical Center, 2014

Presenter, "Microfluidic Technology as an Emerging Clinical Tool to Evaluate Thrombosis and Hemostasis", National Hemophilia Foundation annual meeting, Dallas, Tx., 2015

Presenter, "Pediatric Hospital-Acquired VTE Risk Scores", HTRS annual meeting Session: Pediatric VTE Prevention – Are We There Yet?, Scottsdale, AZ, 2017

Presenter, "The Role of GAS6-MERTK Signaling in Platelet Activation and Thrombus Formation", Johns Hopkins Medical Institute Hematology Section Meeting, Baltimore, MD, 2018

Presenter, "The Role of GAS6-MERTK Signaling in Platelet Activation and Thrombus Formation", Pediatric Hematology/Oncology Conference., Nationwide Children's Hospital: Columbus OH., 2019

Presenter, "Pediatric Venous Thromboembolism", Pediatric Grand Rounds, Arnold Palmer Hospital for Children: Orlando FL., 2019

Presenter, "Translational Research in Pediatric Venous Thromboembolism", Indiana Hemophilia Treatment Center, 2020

Presenter, "Pediatric Venous Thromboembolism", Pediatric Grand Rounds, Children's Hospital and Medical Center: Omaha NE, 2020

Presenter, "The Interplay of Inflammation and Thrombosis", 6th Annual Taru Hays Hematology Symposium, Children's Hospital Colorado, 2021

Presenter, "Translational Research in Pediatric Hospital-Acquired Venous Thromboembolism", Aflac Research Conference, Emory University, 2022

Local

Presenter, "The Role of GAS6-MERTK Signaling in Platelet Activation and Thrombus Formation", Versiti Blood Research Institute: Milwaukee, WI., 2018

Presenter, Responsible Conduct of Research Conference Series. "Collaborative Research", Versiti Blood Center of Wisconsin, 2021

Presenter, "Thrombosis Pathogenesis and Treatment", Versiti Comprehensive Center for Blood Disorders Plasma Academy., 2022

EXTRAMURAL TEACHING:

Medical Student Education

2010 - 2020 University of Colorado School of Medicine, Small Group Leader-Blood & Lymph Pathology
2021 Medical College of Wisconsin, Wauwatosa, WI, Small Group Leader and Clinician Specialist –
Sickle Cell Case-Based Discussion for first year medical students

Resident and Fellow Education

2011 - 2013 Organized bi-weekly Hematology Consult Conference for fellows and attendings

2011 - 2014 Organized monthly Coagulation Conference for fellows and attendings

2012 - Present Supervision and teaching of residents/fellows on inpatient hematology service (6 wks/yr)

2012 - 2020 University of Colorado Hemophilia & Thrombosis Center Clinic, Supervision of
residents/fellows/advanced practice providers (1d/wk)

2018 CHCO Pediatric Resident Academic Half-Day, Curriculum Development and Hematology Instructor

2020 - Present Versiti Comprehensive Center for Blood Disorders ambulatory clinic (1 day/wk),

Supervision of medical students/residents/fellows/advanced practice providers
2020 CHCO Pediatric Resident Academic Half-Day, Curriculum Development and Hematology Instructor

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS

MENTORED:

Undergraduate Students

2018 Drishti Patel, Clinical - Child Health Research Internship Mentor, Pediatric Hospital-Acquired VTE Prevention
2019 Tu Tran, Lab Research Mentor, Platelet Signaling in Thromboinflammation
2022 - Present Iliana Hunsberger, Laboratory, GAS6 levels in healthy vs. inflamed children.
2022 - Present David Sokol, Laboratory

Medical Students

2011 - 2014 Luke Law, Laboratory - Mentored Scholarly Activity Program Mentor, In vitro platelet activation and in vivo thrombosis models
2013 Gilbert Acevedo, Laboratory, In vitro platelet activation & in vivo thrombosis models
2014 - 2016 Natalie Smith, Clinical, Pediatric VTE risk factors and prevention
2015 - 2017 Kelsey Fowlkes, Clinical, Pediatric VTE risk factors and prevention
2016 - 2017 Michael Dittmar, Clinical - Research Mentor, Pediatric Hospital-Acquired VTE Case Detection
2017 - 2018 Bobby Meller, Laboratory - Mentored Scholarly Activity Program Mentor, Inflammatory Mediators & Platelet Signaling in VTE
2017 - 2021 Peter Doan, Clinical - Mentored Scholarly Activity Program Mentor, Superficial Vein Thrombosis and VTE
2019 - Present Kailey Stiles, Clinical Research Mentor, Inflammation and VTE
2019 - Present Taylor Harp, Clinical Research Mentor, Inflammation and VTE
2022 - Present Aly Sonnen, Clinical Advisor

Clinical/Research Fellows

2015 - 2016 Michelle Loi, Clinical - Scholarship Oversight Committee Member, Altitude Effects on Pulmonary Embolism and Biomarkers of Catheter-Associated VTE in Critically Ill Children
2015 - 2017 Jessica Knight-Perry, Clinical - Master's Thesis Committee Member, VTE in cystic fibrosis patients Scholarship Oversight Committee Member
2015 - 2017 Pavel Davizon-Castillo, Laboratory Scholarship Oversight Committee Member, Inflammation and Aging
2017 - 2018 Holly Pacenta, Clinical - Process Improvement Project Mentor, Iron Overload in Chronic Transfusions
2017 - 2019 Emily Rao, Clinical-Scholarship Oversight Committee Member, Clinical Research and Process Improvement Project Mentor, Pediatric Hospital-Acquired VTE
2020 - 2022 Amanda Scheuermann, Clinical - Scholarship Oversight Committee Member, Versiti, DOAC use in children with cancer-related VTE
2021 Alejandra Escobar Vargo, Laboratory - Scholarship Oversight Committee Member, Versiti

Residents

2021 - Present Adam Kidwell, Laboratory - Research Elective Supervisor

Clinical Staff

2013 - 2016 Beth Warren (Pediatric Hematology Instructor), Clinical, Pediatric VTE risk factors/prevention

COMMUNITY SERVICE ACTIVITIES:

2022 Versiti Blood Drive at St. Paul UCC Church, Erin, WI.

ADDITIONAL TRAINING COURSES:

- 2010 University of Colorado: Applications of Molecular and Cell Biology Techniques for the Clinical Investigator
- 2013 - 2014 University of Colorado Denver/Anschutz Medical Campus, Center for Bioethics and Humanities: Responsible Conduct of Research Training
- 2013 - 2014 Colorado Clinical and Translational Sciences Institute (CCTSI), Colorado Mentoring Training (CO-Mentor) Program: Formal training to build practical skills for successful mentoring
- 2020 - 2021 Versiti and Medical College of Wisconsin: Responsible Conduct of Research
- 2020 - 2021 Versiti Medical Sciences Institute: Unconscious Bias Training Program

CONFERENCE RESPONSIBILITIES:

- 2012 - 2019 CHCO Hematology/Oncology Annual Research Conference (Aspen, CO) Co-Director (2016-2019), Moderator/Discussion Leader (2014-15), Presenter (2012-2019)
- 2013 International Society of Thrombosis and Hemostasis (Amsterdam, Netherlands). Session Moderator and Participant – E-poster session
- 2015 Pediatric Academic Society Annual Meeting (San Diego, CA) Pediatric VTE Prevention Session: Moderator and Invited Speaker
- 2017 American Society of Hematology Annual Meeting (Atlanta, GA) Abstract Reviewer, “Disorders of Coagulation or Fibrinolysis” Oral Abstract Session Moderator, “Preclinical Studies in Bleeding Disorders”
- 2022 International Society of Thrombosis and Haemostasis (London, England, UK) Abstract Reviewer, “Thrombosis in Neonates and Children, VTE Prophylaxis, VTE Epidemiology”

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Flood V, Gill J, Morateck P, Christopherson P, Friedman K, Haberichter S, Branchford BR, Hoffman, R, Abshire T, DiPaola J, Hoots K, Leissing C, Lusher J, Ragni M, Shapiro A, Montgomery R. VWF exon 28 polymorphisms associated with decreased VWF:RCo/VWF:Ag ratios. *Blood*. 2010; 116(2): 280-286. PMID 20231421
2. Goldenberg N, Branchford B, Wang M, Durham J, Ray C, Manco-Johnson M. Percutaneous Mechanical and Pharmacomechanical Thrombolysis for Occlusive Deep Venous Thrombosis of the Proximal Limb in Adolescents: Findings from an Institution-Based Prospective Inception Cohort Study of Pediatric Venous Thromboembolism. *J Vasc Interv Radiol* 2011; 22:121-132. PMID 21216157
3. Cooper L, Moore C, Branchford B, Greffe B, Capocelli K, Kuder A, Mehta I, Mourani P. Successful pulmonary artery embolectomy in a patient with a saddle Wilms tumor embolus. *Pediatr Blood & Cancer*. 2012; 58(5):806-9. PMID 21681933
4. Branchford BR, Mourani P, Bajaj L, Manco-Johnson M, Wang M, Goldenberg N. Risk Factors for the Development of In-Hospital Venous Thromboembolism in Children: A Case-Control Study Employing Diagnostic Validation. *Haematologica*. 2012; 97(4):509-15. PMID 22104422
5. Branchford BR, Gibson E, Manco-Johnson M, Goldenberg N. Sensitivity of discharge diagnosis ICD-9 codes for pediatric venous thromboembolism is greater than specificity, but still suboptimal for clinical research. *Thromb Res*. 2012; 129(5):662-3. PMID 22104422
6. Liang X, Branchford B, Greffe B, McGavran L, Carstens B, Meltesen L, Albano E, Quinones R, Cook B, Graham DK. Alk-Positive Extranodal Anaplastic Large Cell Lymphoma with Concurrent MYC Rearrangement in a Pediatric Patient. *J Pediatr Hematol Oncol*. 2013; 35(5):e209-13, PMID 23619105
7. Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffman RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissing C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR. No increase in bleeding identified in type 1 VWD subjects with D1472H Sequence Variation. *Blood*. 2013; 121(18):3742-4. PMID 23520336
8. Zhang W, McIver A, Stashko MA, DeRyckere D, Branchford BR, Hunter D, Kireev D, Miley MJ, Norris-Drouin J, Stewart WM, Lee M, Sather S, Zhou Y, Di Paola JA, Machius M, Janzen WP, Earp HS, Graham DK, Frye SV, Wang X. Discovery of Mer-specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. *J Med Chem*. 2013; 56(23): 9693-700. PMID 23520336
9. Branchford BR, Ruegg K, Vilalobos-Menuet, Jacobson L, Di Paola J, Manco-Johnson M. FVIII/VWF ratio is not a reliable predictor of VWD in children. *Pediatr Blood Cancer*. 2014;61(5): 936-9 PMID 24281894
10. Atchison CM, Arlikar S, Amankwah E, Ayala I, Barrett L, Branchford BR, Streiff M, Takemoto C, Goldenberg NA. Development of a New Risk Score for Hospital-Associated Venous

- Thromboembolism in Non-Critically-Ill Children: Findings from a Large Single-Institutional Case-Control Study. *J. Pediatr.* 2014; 165(4): 793-8. PMID 25064163
11. Amankwah E, Atchison CM, Arlikar S, Ayala I, Barrett L, Branchford BR, Streiff M, Takemoto C, Goldenberg NA. Risk Factors for Hospital-Associated Venous Thromboembolism in the Neonatal Intensive Care Unit. *Thrombosis Research.* 2014; 134(2):305-9. PMID 24953982
 12. Arlikar SJ, Atchison CM, Amankwah EK, Ayala IA, Barrett LA, Branchford BR, Streiff M, Takemoto CM, Goldenberg NA. Development of a new risk score for hospital-associated venous thromboembolism in critically-ill children not undergoing cardiothoracic surgery. *Thrombosis Research.* 2015; 136(4): 717-22. PMID 25979250
 13. Mahajerin A, Branchford BR, Amankwah EK, Raffini L, Chalmers E, van Ommen CH, Goldenberg NA. Hospital-associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk assessment models. *Haematologica.* 2015; 100(8): 1045-50. PMID 26001789
 14. Dittmar M, Smith N, Warren B, Clark B, Wathen B, Hammett K, Reiter P, Hilden J, Goldenberg NA, Branchford B. Improved sensitivity and specificity of pediatric hospital-acquired venous thromboembolism case identification by radiographic designation. *Thrombosis Research.* 2017; 154: 93-95. PMID 2845607
 15. Maloney JP, Branchford BR, Brodsky GL, Cosmic MS, Calabrese DW, Aquilante CL, Maloney KW, Gonzalez JR, Zhang W, Morequ KL, Wiggings KL, Smith NL, Broeckel U, Di Paola J. The ENTPD1 promoter polymorphism 860A>G (rs3814159) is associated with increased gene transcription, protein expression, CD39/NTPDase1 enzymatic activity, and thromboembolism risk. *FASEB J.* 2017. PMID 28302652
 16. Kastelowitz N, Tamura R, Onasoga A, Stalker T, White O, Brown P, Brodsky G, Brass L, Branchford B, Di Paola J, Yin H. Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine. *Sci Rep* 2017 Jun 27;7(1): 4275. PMID: 28655899; PMCID: PMC5487340
 17. Knight-Perry J, Branchford BR, Thornhill D, Martiniano SL, Sagel SD, Wang M. Venous Thromboembolism in Children with Cystic Fibrosis: Retrospective Incidence and Intrapopulation Risk Factors. *Thromb Res.* 2017 Oct; 158:161-166. PMID: 28934665
 18. Atchison, CM, Amankwah E, Wilhelm J, Arlikar S, Branchford BR, Stock A, Streiff M, Takemoto C, Ayala I, Everett A, Stapleton G, Jacobs J, Goldenberg NA. Risk Factors for Hospital-Associated Venous Thromboembolism in Critically-Ill Children Following Cardiothoracic Surgery or Therapeutic Cardiac Catheterisation. *Cardiol in Young.* 2017 Nov 8;1-9. PMID: 29115202
 19. Branchford BR, Mahajerin A, Raffini L, Chalmers E, van Ommen CH, Chan AKC, Goldenberg NA; Recommendations for standardized risk factor definitions in pediatric hospital-acquired venous thromboembolism to inform future prevention trials: Communication from the Subcommittee on Pediatric/Neonatal Hemostasis and Thrombosis of the International Society of Thrombosis and Hemostasis. *J Thromb Haemost.* 2017 Nov; 15(11):2274-2278. PMID: 29027741
 20. Jaffray J, Mahajerin A, Young G, Goldenberg N, Ji L, Spoto R, Stillings A, Krava E, Branchford B. A multi-institutional registry of pediatric hospital acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) Project. *Thromb Res.* 2018 Jan;161:6-72. PMID: 29207321
 21. Newall F, Branchford B, Male C. Anticoagulant prophylaxis and therapy in children: current challenges and emerging issues. *J Throm Haemost.* 2018 Feb; 16(2): 196-208. PMID: 29316202
 22. Branchford BR, Betensky M, Goldenberg NA. Pediatric issues in thrombosis and hemostasis: The how and why of venous thromboembolism risk stratification in hospitalized children. *Thromb Res.* 2018 Dec; 172:190-193. PMID: 29472108
 23. Branchford BR, Stalker TJ, Law L, Acevedo G, Sather S, Brzezinski C, Wilson KM, Minson K, Lee-Sherick AB, Davizon-Castillo P, Ng C, Zhang W, Neeves KB, Lentz SR, Wang X, Frye SV, Earp HS, DeRyckere D, Brass LF, Graham DK, Di Paola JA. The small molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. *J Thromb Haemost.* 2018 Feb;16(2): 352-363. PMID: 29045015
 24. *Commentary in *J Thromb Haemost*: Cosemans JMEM. At the MERcy of platelet primers. *J Thromb Haemost.* 2018 Feb;16(2): 349-351.
 25. Law L, Graham D, Di Paola J, Branchford BR. GAS6/TAM pathway signaling in hemostasis and thrombosis. *Front Med* 2018 May 9; 5:137. PMID: 29868590. PMCID: PMC5954114
 26. Branchford BR and Carpenter, S. The role of inflammation in venous thrombosis. *Front Pediatr.* 2018 May 23;6: 142. PMID: 29876337. PMCID: 5974100
 27. Lyren A, Coffey M, Shepherd M, Lashutka N, Muething S, the SPS Leadership Group. We will not compete on safety: How children's hospitals have come together to hasten harm reduction. *Jt. Comm J Qual*

- Patient Saf. 2018 Jul;44(7):377-388. PMID: 30008350
28. Stoffman JM, Andersson NG, Branchford B, Batt K, D'Orion R, Escuriola Ettingshausen C, Hart DP, Jiminez-Yuste V, Kavakli K, Nogami K, Ramirez C, Wu R. Common themes and challenges in hemophilia care: A multinational perspective. *Hematology*. 2019; 24(1): 39-48. PMID: 30073913
 29. Heizer JW, Shardt TQ, Murphy ME, Branchford BR. Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life. *Thromb Res*. 2019 May; 177:17-22. PMID: 30844684
 30. Majtan T, Park I, Cox A, Branchford BR, di Paola J, Bublil E, Kraus JP. Behavior, body composition, and vascular phenotype of homocystinuric mice on methionine restricted diet or enzyme replacement therapy. *FASEB J*. 2019 Nov; 33(11): 12477-12486. PMID: 31450979
 31. Mahajerin A, Jaffray J, Branchford B, Stilings A, Krava E, Young G, Goldenberg N, Faustino V. Comparative validation study of risk assessment models for pediatric hospital-acquired venous thromboembolism. *J Thromb Haemost*. 2019 Dec. PMID: 31808292
 32. Goldenberg NA, Branchford BR. Commentary: Phase 3 pediatric anticoagulant era. *Blood*. 2020 Feb; 135(7):459-60. PMID:32197268
 33. *Commentary on Brandao LR, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children. *Blood*. 2019 Dec 5: 135(7): 491-504. PMID:31805182
 34. Padhye K, El-Hawary R, Price V, Stevens S, Branchford B, Kulkarni K. Development of a perioperative venous thromboembolism prophylaxis algorithm for pediatric orthopedic surgical patients. *Pediatr Hematol Oncol*. 2020 Mar;37(2):109-118. PMID: 31868065
 35. Perez Botero J, Lee K, Branchford BR, Bray PF, Freson K, Lambert MP, Luo M, Mohan S, Ross JE, Bergmeier W, Di Paola J; Glanzmann Thrombasthenia: genetic basis and clinical correlates. *ClinGen Platelet Disorder Variant Curation Expert Panel*. *Haematologica*. 2020 Apr 5. 105(4):888-894. PMID: 32139434
 36. Loi M, Branchford B, Kim J, Self C, Nuss R. COVID-19 Anticoagulation Recommendations in Children. *Pediatr Blood Cancer*. 2020 Sep;67(9):28485. PMID 32558124
 37. Good RJ, Levin M, Feder S, Loi MM, Kim JS, Branchford BR, Czaja AS, Carpenter TC. Accuracy of bedside ultrasound femoral vein diameter by PICU providers. *Pediatr Crit Care Med*. 2020 Dec;21(12):e1148-e1151. PMID 32639474
 38. Park I, Johnson LK, Haefner K, Cox A, Branchford BR, Cavasin M, di Paola J, Bublil E and Majtan T. Hypermethioninemia leads to increased mortality and coagulopathy in a transgenic I278T mouse model of homocystinuria. *Biomedicines*. 2020 Jul 24;8(8):244. PMID 32722248
 39. Jaffray J, Branchford B, Goldenberg N, Malvar J, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Sposto R, Ji L, Zakai NA, Faustino EVS, Stillings A, Krava E, Young G, Mahajerin A. Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the CHAT Consortium. *J Pediatr*. 2021 Jan;228:252-259. PMID 32920105
 40. MacNevin W, Padhye K, Price V, El-Hawary R, Branchford BR, Stevens S, Kulkarni K. Optimizing pharmacologic thromboprophylaxis use in pediatric orthopedic surgical patients through implementation of a perioperative venous thromboembolism risk screening tool. *Pediatr Blood Cancer*. 2021 Feb;68(2):e28803. PMID 33219749
 41. Ross JE, Zhang BM, Lee K, Mohan S, Branchford BR, Bray P, Dugan SN, Freson K, Heller PG, Kahr WHA, Lambert MP, Luchtman-Jones L, Luo M, Perez-Botero J, Rondina MT, Ryan G, Westbury S, Bergmeier W, Di Paola J. Specifications of the variant curation guidelines for ITGA2B/ITGB3: *ClinGen Platelet Disorder Variant Curation Panel*. *Blood Adv*. 2021 Jan 26;5(2):414-431. PMID 33496739
 42. Doan P, Cox A, Rao E, Branchford B. Temporal and anatomic relationship between superficial and deep vein thrombosis in children. *Thromb Res*. 2021 Apr;200:30-33. PMID 33529870
 43. van Ommen CH, Albisetti M, Bhatt M, Bonduel M, Branchford B, Chalmers E, Chan A, Holzhauer S, Monagle P, Nowak-Gottl U, Revel-Vilk, Sirachainan, Male C for the Subcommittee on Pediatric and Neonatal Hemostasis and Thrombosis. International Pediatric Thrombosis Network to advance pediatric thrombosis research: communication from the Neonatal and Pediatric SSC of the ISTH. *J Thromb Haemost*. 2021 Apr;19(4):1123-1129. PMID 33792176
 44. Hart DP, Branchford BR, Hendry S, Ledniczky, Sidonio RF, Negrier C, Kim M, Rice M, Minshall M, Arce C, Prince S, Kelleher M, Lee S. Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. *Orphanet J Rare Dis*. 2021 Apr 28;16(1):189. PMID: 33910590
 45. Ng CJ, Spomer N, Shearer R, LeBlanc A, Funk S, Manco-Johnson M, Branchford B, Warren B, Buckner

- TW, Moyer G, Wang M, Gibson E, Mashburn C. Improvements in Communication and Coordination of Care in a Hemophilia Treatment Center. *Acta Haematol.* 2021 Apr 29;1-6. PMID: 33915533
46. Warren BB, Chan A, Manco-Johnson M, Branchford BR, Buckner TW, Moyer G, Gibson E, Thornhill D, Wang M, Ng C. Emicizumab Initiation and Bleeding Outcomes in Hemophilia A Patients with and without Inhibitors, a Single-Center Report. *Res Pract Thromb Haemost.* 2021 Aug 3;5(5): e12571. PMID: 34377887
47. Jaffray J, Mahajerin A, Branchford B, Nguyen ATH, Faustino EVS, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Zakai NA, Stillings A, Krava E, Amankwah E, Young G, Goldenberg NA. A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report from the CHAT Consortium. *Pediatr Crit Care Med.* 2022 Jan 1;(23):e1-e9. PMID: 34406168
48. Jaffray J, Baumann-Kreuziger L, Branchford B, Wee CP, Faustino EVS, Zakai N, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Goldenberg NA. Symptomatic pulmonary embolus after catheter removal in children with catheter-related thrombosis: A report from the CHAT Consortium. *J Thromb Haemost.* 2022 Jan;20(1): 133-137. PMID:34523749
49. Jones WL, Ramos CR, Banerjee A, Moore EE, Hansen KC, Coleman JR, Kellher M, Neeves KB, Silliman CC, Di Paola J, Branchford BR. Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength. *Platelets.* 2022 [Accepted, In Press]
50. Scheuermann A, Liegl M, Simpson P, Branchford B, Malec M. Safety and Efficacy of Direct Oral Anticoagulants for Treatment of Venous Thromboembolism in Pediatric Oncology Patients. *J Ped Hematol Oncol.* 2022 [Accepted, In Press].

Books, Chapters, and Reviews

1. Branchford BR, Goldenberg N. "Pediatric Venous Thromboembolism." In: Elzouki (ed), *Textbook of Clinical Pediatrics*, 2nd ed. Lippincott, Williams, and Wilkins; Philadelphia, 2011
2. Branchford BR, Raffini L. "Prophylaxis of Pediatric Thrombosis." In: Manco-Johnson and Goldenberg (ed), *Pediatric Thrombotic Disorders*, 1st ed. Cambridge Univ. Press; New York, 2014
3. Branchford B, DiPaola J. "Analysis of the Bleeding Child." In: Orkin, Nathan, Ginsburg, Look, Fisher, & Lux (ed), *Nathan and Oski's Hematology of Infancy and Childhood*, 8th ed. Saunders Elsevier; Philadelphia, 2014
4. Bernard T, Poisson S, Branchford BR, Nowak-Gottl U. "Coagulation Disorders and Cerebrovascular Disease in Children." In: Swaiman, Ashwal, Ferriero, Schor (ed) *Swaiman's Pediatric Neurology: Principles and Practice*, 6th ed. Saunders Elsevier; Philadelphia, 2016
5. Mahajerin A, Jaffray J, Branchford B. "Prevalence and Risk Factors of Adolescent Venous Thromboembolism" in: Srivaths (ed) *Hematology in the Adolescent Female*, 1st ed. Springer Nature; New York, 2020
6. Branchford BR, Flood VH. "Bleeding and Thrombosis." In: Kleigman, St. Geme, Blum, Shah, Tasker, Wilson (ed) *Nelson Textbook of Pediatrics*, 21st ed. Elsevier; Philadelphia, 2020
7. Branchford BR, Flood VH. "Bleeding and Thrombosis" In: Kliegman, Toth, Bordini, Basel (ed) *Pediatric Symptom-Based Diagnosis: Common Diseases and their Mimics*. 2nd ed. Elsevier; Philadelphia, 2022

Editorials, Letters To Editor, Other

1. Branchford BR, Di Paola J. Making a diagnosis of von Willebrand Disease. *American Society of Hematology Education Program Book*, 2012; 2012:161-7. PMID: 23233576
2. Branchford BR, Monahan PE, Di Paola J. New developments in treatment of pediatric hemophilia and bleeding disorders. *Curr Opin Pediatr.* 2013; 25(1):23-30. PMID: 23274430
3. Branchford B. Clinical and financial impact of HACs: a commentary on clinical and financial costs of hospital-acquired conditions. *Transl Pediatr.* 2015; 4(4):331-3. PMID 26835397
4. Branchford BR, Ng CJ, Neeves KB, Di Paola J. Microfluidic technology as an emerging clinical tool to evaluate thrombosis and hemostasis. *Thrombosis Research.* 2015; 136(1): 13-9. PMID: 26014643
5. Branchford BR, Jaffray J, Mahajerin A. Editorial: Pediatric Venous Thromboembolism. *Front Pediatr.* 2018; 6: 269. PMID: 30320050. PMCID: PMC6170657
6. Branchford BR, Neeves K. New insights into platelet dysfunction in Kawasaki Disease using a microfluidic model of thrombosis. *J Pediatr.* 2020 Aug 11:S0022-3476(20)30998-7. PMID 32795474

Abstracts

1. Friedman K, Bellissimo D, Abshire T, DiPaola J, Hoots W, Lessinger C, Lusher J, Ragni M, Shapiro A,

- Lillicrap D, Goodeve A, Peake I, Montgomery R. "Common VWF Haplotypes in normal African-Americans and Caucasians recruited into the ZPMCB-VWD and their impact on VWF laboratory testing." *Blood*. 2007; 110(11) [Abstract 714]. 2007 American Society of Hematology Annual Meeting: Atlanta, GA
2. Branchford B, Sather S, Brodsky G, White-Adams T, DeRyckere D, Neeves K, Graham D, DiPaola J. "A Novel Splice Variant of the Mer receptor tyrosine kinase functions as an inhibitor of the Gas6/TAM signaling pathway and decreases platelet activation responses." *J Thromb Haemost*. 2011; 9(s2). 2011 International Society of Thrombosis and Hemostasis Scientific Congress: Kyoto, Japan
 3. Branchford B, Sather S, Brodsky G, White-Adams T, DeRyckere D, Neeves K, Graham D, DiPaola J. "iMer Blocks Phosphorylation of the α IIb β 3 Integrin, Decreasing Platelet Activation Responses and Protecting Mice From Arterial Thrombosis." *Blood*. 2011; 118 (11). 2011 American Society of Hematology Annual Meeting: San Diego, CA
 4. Branchford B, Law L, Sather S, Brodsky G, White-Adams T, DeRyckere D, Neeves K, Graham D, DiPaola J. "A novel Gas6/TAM signaling pathway inhibitor decreases platelet activation and arterial thrombosis." 2012 Gordon Conference-Hemostasis: Waterville Valley, NH
 5. Branchford BR, Ramos C, Moore E, Jones W, Silliman C, Banerjee A, Di Paola J. "Human Apolipoprotein A-1 decreases platelet activation responses & protects mice from arterial thrombosis." *Haemophilia*. 2013; 19(s5). 2013 Hemostasis and Thrombosis Research Society Annual Meeting: Charlotte, NC
 6. Jaffray J, Branchford BR, Mahajerin A, Smith N, Goldenberg N, Young G. "Children's Hospital-Acquired Thrombosis Database (CHAT): A Multi-institutional REDCap-Based Database for Prospective Identification of Independent Risk Factors." *Haemophilia*. 2015; 21, e264-5. 2015 Hemostasis and Thrombosis Research Society Annual Meeting: New Orleans, LA
 7. Branchford BR, Jaffray J, Mahajerin A, Goldenberg N, Young G. "Children's Hospital-Acquired Thrombosis Database (CHAT): A Multi-institutional Database for Prospective Identification of Independent Risk Factors." 2015 International Society of Thrombosis and Hemostasis Scientific Congress: Toronto, ON, CAN
 8. Branchford B, Jaffray J, Mahajerin A. "Children's Hospital-Acquired Thrombosis Registry (CHAT): A Multi-Institutional Database for Prospective Identification of Independent Risk Factors" *Pediatr Blood Cancer*. 2016; 63(S1):15. 2016 American Society of Pediatric Hematology/Oncology Annual Meeting, Minneapolis, MN
 9. Doan P, Cox A, Southard E, Clark B, Wathen B, Hammett K, Branchford B. Temporal and Anatomic Relationship Between Superficial and Deep Vein Thromboses in Hospitalized Children. 2018 Thrombosis and Hemostasis Summit of North America, San Diego, CA
 10. Southard E, Cox A, Clark B, Wathen B, Hammett K, Hilden J, Branchford B. Validation of Institutional Clinical Care Guidelines in Predicting Risk of Hospital-Acquired Venous Thromboembolism in an Academic Children's Hospital. 2018 Thrombosis and Hemostasis Summit of North America, San Diego, CA
 11. Branchford B, Cox A, Walker F, Davizon-Castillo P, Ashworth K, Meller R, Di Paola J. GAS6/MERTK-driven platelet activation in thromboinflammation. 2018 Gordon Research Conference - Hemostasis: Waterville Valley, NH
 12. Manco-Johnson M, Thornhill D, Wang M, Boulden Warren B, Ng C, Branchford B, Di Paola J, Ruegg K, Baird C, Jacobson L, Kamyab Hesari N, Smith T. Predictors of Recurrence and Post Thrombotic Syndrome Following Lower Extremity Deep Vein Thrombosis in Children and Adolescents: PTS Risk Reduction Using Thrombolysis as Initial Therapy. 2019 International Society of Thrombosis and Hemostasis Scientific Congress: Melbourne, AU
 13. Mahajerin A, Jaffray J, Stillings A, Krava E, Malvar J, Ji L, Sposto R, Fargo J, Cooper J, Croteau S, Silvey M, Bakeer N, Jalali A, Lonsdale H, Ahumada L, Zakai N, Faustino EV, Goldenberg N, Young G, Branchford B. The Children's Hospital-Acquired Thrombosis (CHAT) Consortium Admission Risk-Assessment Models from Traditional Biostatistics and Machine Learning. 2019 American Society of Hematology annual meeting: Orlando, FL
 14. Jaffray J, Baumann Kreuziger L, Branchford B, Mahajerin A, Phei Wee C, Faustino EVS, Zakai NA, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Goldenberg NA. Pulmonary Embolus after Catheter Removal in Children with Central Venous Catheter Related Venous Thromboembolism: A Report from the CHAT Consortium 2019 American Society of Hematology annual meeting (Virtual)
 15. Stephens E, Nguyen ATH, Jaffray J, Branchford B, Amankwah E, Goldenberg NA, Faustino EV, Zakai NA, Stillings A, Krava E, Young G, Fargo J. Risk of Venous Thromboembolism in Pediatric Hospitalized

- Patients Undergoing Non-Cardiac Surgery: A Report from the CHAT Consortium 2021 Hemostasis and Thrombosis Research Society annual meeting (Virtual)
16. Jaffray J, Mahajerin A, Branchford B, Smith N, Goldenberg N, Young G. Children's Hospital-Acquired Thrombosis Database (CHAT): A Multi-Institutional Database for Prospective Identification of Independent Risk Factors, *Haemophilia*. 21, e264-e265. 2015 Hemophilia and Thrombosis Research Society Annual Meeting: New Orleans, LA
 17. Branchford B, Jaffray J, Mahajerin A, Goldenberg N, Young, G. Children's Hospital-Acquired Thrombosis Database (CHAT): A Multi-Institutional Database for Prospective Identification of Independent Risk Factors, *J Thromb Haemost*. 13:154. 2015 International Society of Haemostasis & Thrombosis Scientific Congress. Toronto, ON, CAN
 18. Mahajerin A, Branchford B, Jaffray J, Vasquez B, Stillings A, Smith N, Goldenberg N, Young G. Children's Hospital-Acquired Thrombosis Database (CHAT): A Multi-Institutional Database for Prospective Identification of Independent Risk Factors *Blood*. 126:1111. 2015 American Society of Hematology Annual Meeting: Orlando, FL
 19. Mahajerin A, Jaffray J, Vasquez B, Sposto R, Branchford B. Patterns of thrombophilia testing in pediatrics: A report from the Children's Hospital-Acquired Thrombosis (CHAT) Registry. 2016 Thrombosis and Hemostasis Summit of North America: Chicago, IL
 20. Branchford B, Jaffray J, Mahajerin A. Children's Hospital-Acquired thrombosis database (CHAT): A multi-institutional database for prospective identification of independent pediatric VTE risk factors. *Pediatr Blood Cancer*. 63(S1):15. 2016 American Society of Pediatric Hematology/Oncology Annual meeting: Minneapolis, MN
 21. Jaffray J, Branchford B, Vasquez B, Stillings A, Smith N, Young G, Mahajerin A. Central venous catheters and pediatric thromboembolism, a report from the children's hospital acquired thrombosis (CHAT) Registry. *J Thromb Haemost*. 14(S1): 90. 2016 International Society of Haemostasis & Thrombosis Scientific Congress: Montpellier, France
 22. Mahajerin A, Jaffray J, Vasquez B, Goldenberg N, Young G, Branchford B. Children's Hospital-Acquired Thrombosis (CHAT) Registry: A Multi-Institutional Registry for Prospective Identification of Independent Risk Factors. *Blood*. 128:2597. 2016 American Society of Hematology Annual Meeting: San Diego, CA
 23. Knight-Perry J, Towler E, Payan M, Branchford BR, Martiniano S, Sagel SD, Wang M. Venous Thromboembolism in Pediatric Cystic Fibrosis. *Blood*. 128:3808. 2016 American Society of Hematology Annual Meeting: San Diego, CA
 24. Ashworth K, Davizon-Castillo P, Johnson L, Branchford B, Bark D, Di Paola J. Platelet alpha-granule deficiency protects local and distal organs in intestinal ischemia reperfusion injury. *Research and Practice in Thrombosis and Haemostasis*. 1: 326. 2017 International Society of Thrombosis and Haemostasis Scientific Congress: Berlin, Germany
 25. Silvey M, Branchford BR, Krava E, Jaffray J, Mahajerin A, Carpenter S. Central venous access-associated thrombosis in congenital heart disease: A preliminary analysis of the Children's Hospital-Acquired Thrombosis (CHAT) database. *Research and Practice in Thrombosis and Haemostasis*. 1: 1191-1192. 2017 International Society of Thrombosis and Haemostasis Scientific Congress: Berlin, Germany
 26. Mahajerin A, Jaffray J, Branchford B, Vasquez B, Sposto R. Patterns of thrombophilia testing in pediatric thrombosis patients: A report from the Children's Hospital-Acquired Thrombosis (CHAT) Database. 2017 Thrombosis and Hemostasis Summit of North America: San Diego, CA
 27. Schardt T, Thornhill D, Branchford B. Comparison of Actual Body Weight, Ideal Body Weight, and Adjusted Body Weight with therapeutic enoxaparin dosing in morbidly obese pediatric patients. 2017 Hemostasis and Thrombosis Research Society Annual Meeting: New Orleans, LA
 28. Ross J, Lee K, Branchford B, Bray P, Dugan S, Freson K, Heller P, Johnson A, Kahr W, Lambert M, Lentaing C, Luo M, Mohan S, Mumford A, Perez-Botero J, Rondina M, Ryan G, Telling L, Westbury S, Zhang B, Bergmeier W, Di Paola J. Specifications of the ACMG/AMP Variant Curation Guidelines for the Analysis of ITGA2B/ITGB3 Sequence Variants: Recommendations by GlinGen's Platelet Disorders Expert Panel. 2019 Curating the Clinical Genome Conference: Washington, D.C.
 29. Manco-Johnson M, Jones K, O'Neil P, Wang M, Boulden Warren B, Davizon-Castillo P, Ng C, Branchford B, Walker F, Smith J, Kamyab Hesari N, Gao B, Di Paola J. Enriched Variants of Coagulation, Platelet, and Related Genes are Common in Adolescents with Idiopathic Occlusive Proximal Deep Vein Thrombosis. 2019 International Society of Thrombosis and Haemostasis Scientific Congress: Melbourne, AU
 30. Manco-Johnson M, Wang M, Boulden Warren B, Buckner T, Moyer G, Jacobson L, Ruegg K, Ng C,

- Branchford B, Di Paola J. Emicizumab Improves Factor X Activation and Thrombin Generation Similar to Mild Hemophilia in Persons with Hemophilia A and Inhibitors. 2019 International Society of Thrombosis and Haemostasis Scientific Congress: Melbourne, AU
31. van Ommen CH, Albisetti M, Bhatt M, Bonduel M, Branchford B, Chalmers E, Chan A, Holzhauer S, Male C, Monagle P, Nowak-Gottl U., Revel-Vilk S. International Pediatric Thrombosis Network: Advancing the field of pediatric Thrombosis 2019 International Society of Thrombosis and Haemostasis Scientific Congress: Melbourne, AU
 32. Arce C, Branchford B, Hart D, Hendry S, Kelleher M, Kim M, Ledniczky R, Lee M, Lee S, Minshall M, Negrier C, Prince S, Rice M, Sidonio R. Optimizing language for effective communication of gene therapy concepts: a qualitative study. 2019 National Hemophilia Foundation annual meeting: Anaheim, CA
 33. Jaffray J, Mahajerin A, Branchford B, Nguyen AY, Amankwah E, Silvey M, Croteau S, Cooper J, Fargo J, Bakeer N, Stillings A, Krava E, Faustino V, Zakai NA, Young G, Goldenberg N. Assessing Venous Thromboembolism Risk in Critically-Ill Children: A Report from the Children's Hospital-Acquired Thrombosis (CHAT) Consortium 2019 American Society of Hematology annual meeting: Orlando, FL
 34. Stiles K, Harp T, Cox A, Branchford B. Association Between Inflammation and Hospital-Acquired Venous Thrombosis in Pediatric Patients: A Report from the CHAT Registry. 2020 American College of Osteopathic Physicians Spring Conference (Virtual).
 35. MacNevin W, Padhye K, Price V, El-Hawary R, Branchford BR, Stevens S, Kulkarni K. Validation and Impact of a Perioperative Venous Thromboembolism Prophylaxis Algorithm for Pediatric Orthopedic Surgical Patients. (Abstract PB1281) 2020 International Society of Thrombosis and Haemostasis Scientific Congress (Virtual)
 36. Warren BB, Thornhill D, Smith J, Shearer R, Moyer G, Fox L, O'Connell M, Horton R, Funk S, Chan A, Gibson E, Ng C, Buckner TW, Branchford B Manco-Johnson MJ, Wang M. Emicizumab, beyond Annualized Bleeding Rates: Real World Joint Health and Physical Activity Data. (Abstract PB1161) 2020 International Society of Thrombosis and Haemostasis Congress (Virtual)
 37. Moyer G, Warren BB, Jacobson L, Baird CH, Thornhill D, Smith J, Ng C, Buckner TW, Branchford B, Wang M, Manco-Johnson MJ. Emicizumab, beyond Annualized Bleeding Rates: Do Laboratory Assays Help Predict Emicizumab Effects? (Abstract PB1164) 2020 International Society of Thrombosis and Haemostasis Congress (Virtual)
 38. Warren BB, Taylor J, Branchford B, Ng C, Ambruso D, Briones N, Tran A, Jacobson L, Thornhill D, Moyer G, Norton K, Buckner TW, Wang M, Manco-Johnson MJ. Emicizumab, beyond Annualized Bleeding Rates: How Does Emicizumab Affect Bone Biomarkers? (Abstract PB1165) 2020 International Society of Thrombosis and Haemostasis Congress (Virtual)
 39. Buckner TW, Rapacchietta O, Hill D, Thornhill D, Smith J, Shearer R, Ng C, Branchford B, Moyer G, Manco-Johnson MJ, Wang M. Improved Prophylaxis Adherence After Switching to Emicizumab: Real World Data from a Single Center. (Abstract PB0937) 2020 International Society of Thrombosis and Haemostasis Congress (Virtual)
 40. van Ommen CH, Albisetti M, Bhatt M, Bonduel M, Bordbar M, Branchford B, Chalmers E, Chan A, Holzhauer S, Jaffray J, Male C, Monagle P, Nowak-Gottl U, Raffini L, Revel-Vilk S, Sirachainan N, IPTN Consortium. The Throm-PED Registry: The Cornerstone of the International Pediatric Thrombosis Network. (Abstract PB1289)
 41. 2020 International Society of Thrombosis and Haemostasis Congress (Virtual)
 42. Chan A, Warren BB, Ng C, Buckner TW, Moyer G, Furton L, Branchford B, Manco-Johnson M, Wang M. Influence of Emicizumab on Patient Lifestyle at the University of Colorado. 2020 World Federation of Hemophilia Conference (Virtual)
 43. Springborn S, Schulte M, Kipp M, Ghosh S, Rothlin C, Branchford B. Prothrombotic Phenotype of a Protein S Mutant Lacking Anticoagulant Activity (Abstract 2098). 2021 American Society of Hematology Annual Meeting, Atlanta, GA, USA